1Lyn Patrick, ND. Nonalcohlolic fatty liver disease: relationship to insulin sensitivity and oxidative stress [ J ]. Altern Med Rev, 2002,7 (4): 276 -291.
2Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow- up in an Italian population[J]. Dig Dis Sci, 1997,42:1428 - 1432.
3Andy S Yu, Emmet B Keeffe. Nonalcoholic fatty liver disease[J]. Gastroenterol Disord,2002,2(1): 11 - 19.
4Day CP. Steatohepatitis: a tale of two "hits"? [J]. Gastroenterology,1998,114:842 - 845.
5Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restrivted diet and exercise in obese patients with fatty liver[J]. J Hetatol, 1997,27:103- 107.
6Giulio Marchesini, Mara Brizi. Meffomin in non- alcoholic statobepatitis[J] .The Lancet,2001,358:893 - 894.
7Nair S, Diehl AM, Perrillo R. Mefformin in non - alcoholic steatohpatitis(NASH): efficacy and safety: a preliminary report [ J ]. Gastroenterology,2002,1222:621.
8Lin HZ, Yang SQ, Chuckaree C, et al. Mefforin reverses fatty liver disease in obese, leptin deficient mice[ J]. Nat Med, 2000,6: 998 - 1003.
9Caldwell SH, Hespenheide EE, Redick JA, et al. A polit study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis [ J ]. Am J Gastroenterol, 2001,96:519 - 525.
10Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children : A pilot study[ J]. J Pediatr, 2000,136: 734 - 738.
